Clinical trials: Pandemic Influenza
Pandemic Influenza
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors as prophylaxis against pandemic influenza infection in patients who are prescribed a long term course in the context of a place of employment or…
- Trial name
- PIPET B (NCT00640211)
- Where
- 8 sites in Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kirby Institute
Viral Respiratory Infection (e.g., Influenza), Bacterial Respiratory Infections
Respiratory Pathogen Distribution During and After the COVID-19 Pandemic
This retrospective observational study aims to evaluate changes in the prevalence and distribution of respiratory pathogens detected by multiplex respiratory polymerase chain reaction (PCR) testing during and after the SARS-CoV-2…
- Trial name
- NCT07601126
- Where
- Turkey (Türkiye)
- Volunteers
- 537 people
- Sponsor
- Hisar Intercontinental Hospital
Influenza
Outcomes of Pandemic Influenza in Pregnancy
We propose to follow a cohort of pregnant and post-partum Canadian women through the fall and winter of 2009/2010 and the anticipated second and third waves of the current pandemic in order to better understand the incidence…
- Trial name
- NCT01322516
- Where
- 8 sites in Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
H1N1 Influenza
H1N1 Vaccine Safety in Manitoba, Canada
Many people worldwide received the monovalent adjuvanted H1N1 vaccine. However, very little is known about the safety of the vaccine, particularly beyond the first few weeks after vaccination.
- Trial name
- NCT01421251
- Where
- Canada
- Volunteers
- 800,000 people
- Sponsor
- International Centre for Infectious Diseases, Canada
Influenza, Swine-origin A/H1N1 Influenza
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00956046
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated), Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
- Where
- 15 sites in Finland
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Influenza
Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants
A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine (PANFLU.1).
- Trial name
- NCT01047202
- Testing
- Pandemic influenza A/H1N1 vaccine, Seasonal trivalent vaccine
- Where
- China
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03023176
- Testing
- Fluzone® standard IIV3, Fluzone® standard IIV3 Pediatric Dose
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza, Swine-Origin A/H1N1 Influenza Virus
Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults
This study is designed to assess the safety of the approved and licensed HUMENZA (adjuvanted A/H1N1 pandemic influenza vaccine) and PANENZA (non-adjuvanted A/H1N1 pandemic influenza vaccine) to meet regulatory requirements for…
- Trial name
- NCT01032980
- Where
- 5 sites in France
- Volunteers
- 3,934 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00972517
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 8 sites in Germany
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
H1N1/2009 Influenza
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults
The purpose of this study is to assess the safety and effectiveness (immune response) to a licensed H1N12009 influenza vaccine in aboriginal children and adults.
- Trial name
- NCT01001026
- Testing
- Arepanrix
- Where
- 5 sites in Canada
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- David Scheifele
Influenza
Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 6 and 35 months.
- Trial name
- NCT00971321
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of a Pandemic Influenza Vaccine in Children
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza strain H5N1 is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00370864
- Testing
- H5N1 pandemic influenza vaccine
- Where
- 2 sites in Australia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Seqirus
Immunologic Tests
A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines
The purpose of this exploratory, retrospective laboratory study is to assess the humoral immune response to H1 hemagglutinin stalk domain and other influenza A virus protein epitopes following administration, in adults and…
- Trial name
- NCT02415842
- Testing
- Serum samples
- Where
- United States
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Spondyloarthritis
Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
The prognosis of rheumatic diseases has improved considerably with development of therapy. However, infections are considered the most important cause of morbidity and mortality in this group of patients.
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM)
- Trial name
- NCT01151644
- Testing
- Anti-pandemic H1N1 influenza vaccine
- Where
- Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Influenza
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
The aim of this study is to investigate the immunogenicity and safety of the inactivated split-virion vaccine in infants.
- Trial name
- NCT01494740
- Testing
- split-virion, non-adjuvanted vaccine of 7.5 μg, split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted vaccine of seasonal influenza
- Where
- China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children
This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic. Study objectives: To describe the safety profiles in the periods following each vaccination in subjects receiving…
- Conditions
- Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections
- Trial name
- NCT00884182
- Testing
- A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
- Where
- 13 sites in Finland
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
The purpose of the study is to investigate and compare the human immune response in epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza vaccine (LAIV) in adults and in children.
- Trial name
- NCT03023683
- Testing
- FluMist®
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children
The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.
- Trial name
- NCT01323946
- Testing
- GSK Biologicals' investigational vaccine GSK1562902A
- Where
- 6 sites in Australia, Singapore
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline